NCT03263429View on ClinicalTrials.gov

Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 23, 2017

Primary Completion Date

August 15, 2023

Study Completion Date

December 21, 2023

Conditions
Colorectal CancerMetastatic Colorectal CancerRAS Wild Type Colorectal CancerRefractory Colorectal Cancer
Interventions
DRUG

Glutaminase Inhibitor CB-839

Given by mouth

BIOLOGICAL

Panitumumab

Given by vein

DRUG

Irinotecan Hydrochloride (phase I only)

Given by vein

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DEVICE

Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans

During phase II at baseline and day 28 of cycle 1

Trial Locations (1)

37232

Vanderbilt-Ingram Cancer Center, Nashville

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Calithera Biosciences, Inc

INDUSTRY

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT03263429 - Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer | Biotech Hunter | Biotech Hunter